SETDB1 and neoplasm: A deeper understanding of the molecular mechanisms of SETDB1 that regulate ERVs and immune genes in both tumour and normal cells and the availability of more selective and effective SETDB1 inhibitors may lead to SETDB1 targeting as a promising antitumour epigenetic therapy.